Teva Announces Ambitious Revenue Forecast For 2015

In a recent investor presentation, Teva announced that it plans to generate revenues of around US$31bn by 2015 in line with its more broadly optimistic outlook for an increase in generic drug sales globally. BMI believes Teva is in a strong position to realise its forecast - chiefly through its experience in securing exclusivity periods after patent expiries and give it significant first mover advantages in one of its largest regional markets by

To read the full article, please choose one of the following options: